Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2007

Open Access 01-12-2007 | Research

Differential expression and role of p21cip/waf1 and p27kip1 in TNF-α-induced inhibition of proliferation in human glioma cells

Authors: Pabbisetty Sudheer Kumar, Anjali Shiras, Gowry Das, Jayashree C Jagtap, Vandna Prasad, Padma Shastry

Published in: Molecular Cancer | Issue 1/2007

Login to get access

Abstract

Background

The role of TNF-α in affecting the fate of tumors is controversial, while some studies have reported apoptotic or necrotic effects of TNF-α, others provide evidence that endogenous TNF-α promotes growth and development of tumors. Understanding the mechanism(s) of TNF-α mediated growth arrest will be important in unraveling the contribution of tissue associated macrophages in tumor resistance. The aim of this study was to investigate the role of Cyclin Dependent Kinase Inhibitors (CDKI) – p21cip/waf1 and p27kip1 in TNF-α mediated responses in context with p53 and activation of NF-κB and Akt pathways. The study was done with human glioma cell lines -LN-18 and LN-229 cells, using monolayer cultures and Multicellular Spheroids (MCS) as in vitro models.

Results

TNF-α induced inhibition of proliferation and enhanced the expression of p21cip/waf1 and p27kip1 in LN-18 cells. p21 was induced on exposure to TNF-α, localized exclusively in the nucleus and functioned as an inhibitor of cell cycle but not as an antiapoptotic protein. In contrast, p27 was constitutively expressed, localized predominantly in the cytoplasm and was not involved in arrest of proliferation. Our data using IκBα mutant LN-18 cells and PI3K/Akt inhibitor-LY294002 revealed that the expression of p21 is regulated by NF-κB. Loss of IκBα function in LN-229 cells (p53 positive) did not influence TNF-α induced accumulation of pp53 (Ser-20 p53) suggesting that p53 was not down stream of NF-κB. Spheroidogenesis enhanced p27 expression and p21 induced by TNF-α was significantly increased in the MCS compared to monolayers.

Conclusion

This study demarcates the functional roles for CDKIs-p21cip/waf1 and p27kip1 during TNF-α stimulated responses in LN-18 glioma cells. Our findings provide evidence that TNF-α-induced p21 might be regulated by NF-κB or p53 independently. p21 functions as an inhibitor of cell proliferation and does not have a direct role in rendering the cells resistant to TNF-α mediated cytotoxicity.
Appendix
Available only for authorised users
Literature
1.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002, 61: 215-225.PubMed
2.
Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev. 1995, 21: 128-151. 10.1016/0165-0173(95)00010-0CrossRefPubMed
3.
Badie B, Schartner J: Role of microglia in glioma biology. Microsc Res Tech. 2001, 54: 106-113. 10.1002/jemt.1125CrossRefPubMed
4.
Ledgerwood EC, Pober JS, Bradley JR: Recent advances in the molecular basis of TNF signal transduction. Lab Invest. 1999, 79: 1041-1050.PubMed
5.
Goeddel DV, Aggarwal BB, Gray PW, Leung DW, Nedwin GE, Palladino MA, Patton JS, Pennica D, Shepard HM, Sugarman BJ: Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol. 1986, 51 (Pt 1): 597-609.CrossRefPubMed
6.
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM: Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985, 230: 943-945. 10.1126/science.3933111CrossRefPubMed
7.
Danforth DN, Sgagias MK: Tumour necrosis factor-alpha modulates oestradiol responsiveness of MCF-7 breast cancer cells in vitro. J Endocrinol. 1993, 138: 517-528.CrossRefPubMed
8.
Ruggiero V, Latham K, Baglioni C: Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol. 1987, 138: 2711-2717.PubMed
9.
Cai Z, Korner M, Tarantino N, Chouaib S: IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J Biol Chem. 1997, 272: 96-101. 10.1074/jbc.272.1.96CrossRefPubMed
10.
Jeoung DI, Tang B, Sonenberg M: Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem. 1995, 270: 18367-18373. 10.1074/jbc.270.31.18367CrossRefPubMed
11.
Wiedenmann B, Reichardt P, Rath U, Theilmann L, Schule B, Ho AD, Schlick E, Kempeni J, Hunstein W, Kommerell B: Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol. 1989, 115: 189-192. 10.1007/BF00397922CrossRefPubMed
12.
Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999, 285: 260-263. 10.1126/science.285.5425.260CrossRefPubMed
13.
Wilson J, Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002, 12: 113-120. 10.1006/scbi.2001.0419CrossRefPubMed
14.
Villeneuve J, Tremblay P, Vallieres L: Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res. 2005, 65: 3928-3936. 10.1158/0008-5472.CAN-04-3612CrossRefPubMed
15.
16.
Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.CrossRefPubMed
17.
Cayrol C, Knibiehler M, Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998, 16: 311-320. 10.1038/sj.onc.1201543CrossRefPubMed
18.
Gartel AL: The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res. 2005, 29: 1237-1238. 10.1016/j.leukres.2005.04.023CrossRefPubMed
19.
Gartel AL, Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005, 65: 3980-3985. 10.1158/0008-5472.CAN-04-3995CrossRefPubMed
20.
Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, el-Deiry WS, Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, el-Deiry WS, Tyner AL: p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res. 1996, 227: 171-181. 10.1006/excr.1996.0264CrossRefPubMed
21.
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994, 8: 9-22. 10.1101/gad.8.1.9CrossRefPubMed
22.
Barnes A, Pinder SE, Bell JA, Paish EC, Wencyk PM, Robertson JF, Elston CW, Ellis IO: Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol. 2003, 201: 451-459. 10.1002/path.1464CrossRefPubMed
23.
Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000, 183. 10.17.CrossRefPubMed
24.
25.
Hamilton G: Multicellular spheroids as an in vitro tumor model. Cancer Lett. 1998, 131: 29-34. 10.1016/S0304-3835(98)00198-0CrossRefPubMed
26.
Kunz-Schughart LA, Kreutz M, Knuechel R: Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol. 1998, 79: 1-23. 10.1046/j.1365-2613.1998.00051.xPubMedCentralCrossRefPubMed
27.
Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol. 1997, 273: C1109-C1123.PubMed
28.
Sutherland RM, Rasey JS, Hill RP: Tumor biology. Am J Clin Oncol. 1988, 11: 253-274. 10.1097/00000421-198806000-00004CrossRefPubMed
29.
Drewinko B, Patchen M, Yang LY, Barlogie B: Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 1981, 41: 2328-2333.PubMed
30.
Vandenabeele P, Declercq W, Beyaert R, Fiers W: Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995, 5: 392-399. 10.1016/S0962-8924(00)89088-1CrossRefPubMed
31.
Yu C, Takeda M, Soliven B: Regulation of cell cycle proteins by TNF-alpha and TGF-beta in cells of oligodendroglial lineage. J Neuroimmunol. 2000, 108: 2-10. 10.1016/S0165-5728(99)00278-7CrossRefPubMed
32.
Schumm K, Rocha S, Caamano R, Perkins ND: Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J. 2006, 25: 4820-4832. 10.1038/sj.emboj.7601343PubMedCentralCrossRefPubMed
33.
Naumann U, Durka S, Weller M: Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?. Oncogene. 1998, 17: 1567-1575. 10.1038/sj.onc.1202071CrossRefPubMed
34.
Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002, 1: 639-649.PubMed
35.
Blain SW, Massague J: Breast cancer banishes p27 from nucleus. Nat Med. 2002, 8: 1076-1078. 10.1038/nm1002-1076CrossRefPubMed
36.
Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002, 8: 1136-1144. 10.1038/nm762CrossRefPubMed
37.
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001, 3: 245-252. 10.1038/35060032CrossRefPubMed
38.
Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem. 2002, 277: 11352-11361. 10.1074/jbc.M109062200CrossRefPubMed
39.
Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: p27/Kip1 mutation found in breast cancer. Cancer Res. 1996, 56: 2400-2404.PubMed
40.
Alleyne CH, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ: Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol. 1999, 14: 1111-1116.PubMed
41.
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18: 1571-1583. 10.1093/emboj/18.6.1571PubMedCentralCrossRefPubMed
42.
Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G: Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer. 2003, 89: 1920-1926. 10.1038/sj.bjc.6601398PubMedCentralCrossRefPubMed
43.
St CB, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996, 2: 1204-1210. 10.1038/nm1196-1204CrossRef
44.
Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995, 11: 2021-2028.PubMed
45.
Javelaud D, Wietzerbin J, Delattre O, Besancon F: Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in Ewing tumor cells. Oncogene. 2000, 19: 61-68. 10.1038/sj.onc.1203246CrossRefPubMed
46.
Pennington KN, Taylor JA, Bren GD, Paya CV: IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol. 2001, 21: 1930-1941. 10.1128/MCB.21.6.1930-1941.2001PubMedCentralCrossRefPubMed
47.
Glaser T, Wagenknecht B, Weller M: Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene. 2001, 20: 4757-4767. 10.1038/sj.onc.1204498CrossRefPubMed
48.
Yamamoto M, Fukushima T, Hayashi S, Ikeda K, Tsugu H, Kimura H, Soma G, Tomonaga M: Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res. 2000, 20: 611-618.PubMed
49.
Anto RJ, Venkatraman M, Karunagaran D: Inhibition of NF-kappaB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. J Biol Chem. 2003, 278: 25490-25498. 10.1074/jbc.M301790200CrossRefPubMed
50.
Hellin AC, tires-Alj M, Verlaet M, Benoit V, Gielen J, Bours V, Merville MP: Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis. J Pharmacol Exp Ther. 2000, 295: 870-878.PubMed
51.
Sheau-Yann Shieh, Yoichi Taya, Carol Prives: DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 1999, 18: 1815-1823. 10.1093/emboj/18.7.1815CrossRef
52.
Steegenga WT, van der Eb AJ, Jochemsen AG: How Phosphorylation Regulates the Activity of p53. J Mol Biol. 1996, 263: 103-113. 10.1006/jmbi.1996.0560CrossRefPubMed
53.
Tamar Unger, Tamar Juven-Gershon, Eli Moallem, Michael Berger, Ronit Vogt Sionov, Guillermina Lozano, Moshe Oren, Ygal Haupt: Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999, 18: 1805-1814. 10.1093/emboj/18.7.1805CrossRef
54.
James Jabbur, Peng Huang, Wei Zhang: DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene. 2000, 19: 6203-6208. 10.1038/sj.onc.1204017CrossRef
55.
Zoya Demidenko, Mikhail Blagosklonny: Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor. Cancer Res. 2004, 64: 3653-3669. 10.1158/0008-5472.CAN-04-0204CrossRef
56.
Xie HL, Su Q, He XS, Liang XQ, Zhou JG, Song Y, Li YQ: Expression of p21WAF1 and p53 and polymorphism of p21WAF1 gene in gastric carcinoma. World J Gastroenterol. 2004, 10: 1125-1131.CrossRefPubMed
57.
Drané P, Leblanc V, Miro-Mur F, Saffroy R, Debuire B, May E: Accumulation of an inactive form of p53 protein in cells treated with TNFα. Cell Death Differ. 2002, 9: 527-537. 10.1038/sj.cdd.4400983CrossRefPubMed
58.
Nan-Shan Chang: The Non-ankyrin C Terminus of IκBα Physically Interacts with p53 in Vivo and Dissociates in Response to Apoptotic Stress, Hypoxia, DNA Damage, and Transforming Growth Factor-β1-mediated Growth Suppression. J Biol Chem. 2002, 277: 10323-10331. 10.1074/jbc.M208647200CrossRef
59.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1038/43466CrossRefPubMed
60.
Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998, 8: 1195-1198. 10.1016/S0960-9822(07)00493-9CrossRefPubMed
61.
LaRue KE, Bradbury EM, Freyer JP: Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts. Cancer Res. 1998, 58: 1305-1314.PubMed
Metadata
Title
Differential expression and role of p21cip/waf1 and p27kip1 in TNF-α-induced inhibition of proliferation in human glioma cells
Authors
Pabbisetty Sudheer Kumar
Anjali Shiras
Gowry Das
Jayashree C Jagtap
Vandna Prasad
Padma Shastry
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-6-42

Other articles of this Issue 1/2007

Molecular Cancer 1/2007 Go to the issue

Research

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells

Review

Contribution of oncoproteomics to cancer biomarker discovery

Research

Role of PP2Cα in cell growth, in radio- and chemosensitivity, and in tumorigenicity

Research

In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors

Research

Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells

Research

Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits